KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Cognitive-Behavioral Intervention for Children With Hematological Cancer Receiving Chemotherapy: A Randomized Controlled Trial. PMID 39828642 · Psychooncology · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial. PMID 39821945 · J Clin Hypertens (Greenwich) · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial. PMID 39820125 · Nat Cancer · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of a developed module in improving quality of life among breast cancer patients undergoing chemotherapy at Institut Kanser Negara. PMID 39812432 · Med J Malaysia · 2025-Jan The study is an original RCT in breast cancer patients with a drug-containing intervention, but its primary efficacy endpoints are quality of life and depression, not a time-to-event outcome (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis. The study phase is not explicitly stated. Therefore, it does not meet the required criteria for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. PMID 39810771 · Kidney Int Rep · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis. PMID 39810768 · Kidney Int Rep · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: A randomized-controlled trial. PMID 39802807 · JHEP Rep · 2025-Jan The study is a randomized controlled trial in oncology (HCC) with time-to-event endpoints, but the intervention is a procedural/ablation technique (MWA vs. RFA) and does not meet the required 'drug-containing intervention' criterion. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial. PMID 39802302 · EClinicalMedicine · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial. PMID 39800452 · J Prev Alzheimers Dis · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. PMID 39790009 · Eur J Neurol · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. PMID 39777610 · Dermatol Ther (Heidelb) · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Preoperative Physical Activity Improvement with the Use of Activity Trackers in Patients Undergoing Radical Cystectomy-A Bicentric, Open-label, Randomised Controlled Trial: A Clinical Study Protocol of the PreAct Trial. PMID 39758853 · Eur Urol Open Sci · 2025-Jan 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Influence of Regular Statin Intake on Prostate-Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau). PMID 39757796 · Cancer Med · 2025-Jan The record describes a secondary analysis of a drug's effect within a screening trial, not a formal Phase III/IIIb or Phase II/III randomized trial of a novel anti-cancer drug for a definitive oncology indication.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. PMID 39756446 · Lancet Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Informative censoring in externally controlled clinical trials: a potential source of bias. PMID 39754980 · ESMO Open · 2025-Jan The record describes a methodological simulation study on informative censoring in cancer clinical trials. While it involves oncology, human data, randomized trial designs, and a Phase III context, it is not an original report of a clinical trial with a drug intervention and a time-to-event efficacy endpoint. It is a research article analyzing bias, not presenting trial results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proteomic changes upon treatment with semaglutide in individuals with obesity. PMID 39753963 · Nat Med · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. PMID 39753962 · Nat Med · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It? PMID 39753813 · Curr Oncol Rep · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation. PMID 39739990 · Clin Transplant · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis. PMID 39737542 · Cancer Med · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Mineralocorticoid receptor antagonists in heart failure with preserved/mildly reduced ejection fraction: from TOPCAT to FINEARTS-HF]. PMID 39714499 · G Ital Cardiol (Rome) · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). PMID 39710508 · J Gynecol Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of a 72-h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy-protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated COMBAT-ARF trial. PMID 39704260 · Acta Anaesthesiol Scand · 2025-Jan 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT. PMID 39700682 · Lung Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. PMID 39693627 · NEJM Evid · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. PMID 39690897 · Mult Scler · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). PMID 39686620 · J Alzheimers Dis · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial. PMID 39678704 · Lancet Reg Health Eur · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial. PMID 39675376 · Lancet Oncol · 2025-Jan While the study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it fails the critical criterion of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with associated KM/HR data. The reported endpoints are HRQOL and IBTR (not yet reported), making the study ineligible.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial. PMID 39671779 · Gynecol Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults. PMID 39652202 · Eur J Drug Metab Pharmacokinet · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial. PMID 39644907 · Lancet Haematol · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. PMID 39644535 · Eur J Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii. PMID 39644103 · Expert Rev Anti Infect Ther · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). PMID 39636571 · Adv Ther · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of probiotics on clinical manifestations and inflammatory markers in HTLV-1-associated myelopathy/tropical spastic paraparesis: A triple blind randomized, placebo controlled trial. PMID 39631261 · Cytokine · 2025-Jan The study is a randomized controlled trial of a probiotic intervention for HTLV-1-associated myelopathy/tropical spastic paraparesis, which is a neurological condition, not a malignant neoplasm (oncology). It does not report a time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not specified as Phase III/IIIb.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Epilepsy core outcome set for effectiveness trials (EPSET): A systematic review of outcomes measured in registered phase III and IV clinical trials for adults with epilepsy. PMID 39626527 · Epilepsy Res · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). PMID 39625230 · Curr Med Res Opin · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia. PMID 39618256 · Curr Med Res Opin · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. PMID 39617030 · Lancet Neurol · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014). PMID 39615333 · Eur J Cancer · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials. PMID 39613950 · Target Oncol · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. PMID 39612919 · Lancet Oncol · 2025-Jan The trial is oncology, human, randomized, phase 3, and has a drug intervention with a primary result report. However, the primary and only reported efficacy endpoint is pathological complete response (pCR), a binary endpoint. There is no evidence of a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with associated KM data or HR, which is required for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission. PMID 39606837 · Future Oncol · 2025-Jan The record is a protocol for a randomized, open-label trial (REGAL) of galinpepimut-S in AML. It is oncology, human, randomized, involves a drug intervention, and is an original protocol document. However, it is not an original result report, does not present any efficacy data or time-to-event endpoints, and is a protocol, not a results publication.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. PMID 39602990 · Eur J Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of a Dedicated Device for Cerebral Venous Thrombectomy: A Pilot Randomized Clinical Trial. PMID 39601121 · Stroke · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. PMID 39586309 · Lancet Diabetes Endocrinol · 2025-Jan While the study meets most criteria (oncology, human, randomized, phase 3, drug intervention, original results), it is ineligible because the primary efficacy endpoint is a binary proportion (event-free proportion at 5 years) for non-inferiority assessment, not a time-to-event endpoint suitable for Kaplan-Meier digitization (e.g., OS, PFS, DFS with time-to-event analysis or hazard ratio). The deterministic review's 'no_time_to_event_signal' is correct.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. PMID 39586304 · Lancet Rheumatol · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. PMID 39571587 · Lancet Gastroenterol Hepatol · 2025-Jan The record describes a randomized, double-blind, Phase III trial of vedolizumab for Crohn's disease recurrence. While it meets criteria for being a human, randomized, Phase III drug-intervention trial with original results, it is excluded because it is non-oncology (Crohn's disease) and the primary endpoint is not a time-to-event efficacy outcome (it is a categorical endoscopic score).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis. PMID 39561927 · Clin Immunol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -